Ignite Creation Date:
2024-05-06 @ 5:29 PM
Last Modification Date:
2024-10-26 @ 2:29 PM
Study NCT ID:
NCT05322720
Status:
NOT_YET_RECRUITING
Last Update Posted:
2022-04-12
First Post:
2022-03-10
Brief Title:
HR Positive HER2 Negative Advanced Breast Cancer With Progression After Endocrine Therapy
Sponsor:
Taizhou EOC Pharma Co Ltd
Organization:
Taizhou EOC Pharma Co Ltd
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-04
Start Date Type:
ESTIMATED
Primary Completion Date:
2023-03
Primary Completion Date Type:
ESTIMATED
Completion Date:
2025-05
Completion Date Type:
ESTIMATED
First Submit Date:
2022-03-10
First Submit QC Date:
April 7 2022
Study First Post Date:
2022-04-12
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2022-04-07
Last Update Post Date:
2022-04-12
Last Update Post Date Type:
ACTUAL